|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
|
|
2
|
Gottardo F, Liu CG, Ferracin M, et al:
Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Escudier B: Advanced renal cell carcinoma:
current and emerging management strategies. Drugs. 67:1257–1264.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Broghammer EL and Ratliff TL:
Immunotherapy of urologic tumors: principles and progress. Urol
Oncol. 7:45–56. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mulders P, Figlin R, deKernion JB, et al:
Renal cell carcinoma: recent progress and future directions. Cancer
Res. 57:5189–5195. 1997.PubMed/NCBI
|
|
6
|
Bukowski RM, Eisen T, Szczylik C, et al:
Final results of the randomized phase III trial of sorafenib in
advanced renal cell carcinoma: Survival and biomarker analysis. J
Clin Oncol. 25:50232007.
|
|
7
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J
Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hudes G, Carducci M, Tomczak P, et al:
Temsirolimus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar
|
|
9
|
Escudier B, Pluzanska A, Koralewski P, et
al: Bevacizumab plus interferon alfa-2a for treatment of metastatic
renal cell carcinoma: a randomised, double-blind phase III trial.
Lancet. 370:2103–2111. 2007. View Article : Google Scholar
|
|
10
|
Jonasch E, Wood CG, Matin SF, et al: Phase
II presurgical feasibility study of bevacizumab in untreated
patients with metastatic renal cell carcinoma. J Clin Oncol.
27:4076–4081. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sternberg CN, Davis ID, Mardial J, et al:
Pazopanib in locally advanced or metastatic renal cell carcinoma:
results of a randomised phase III trial. J Clin Oncol.
28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Motzer RJ, Escudier B, Oudard S, et al:
Phase 3 trial of everolimus for metastatic renal cell carcinoma:
final results and analysis of prognostic factors. Cancer.
116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Walsh PC, Retik AB, Vaugh ED, et al:
Campbell’s Urology. 8th edition. WB Saunders Company; Philadelphia,
PA: pp. 2672–2719. 2002
|
|
14
|
Chen X, Ba Y, Ma L, et al:
Characterization of microRNAs in serum: a novel class of biomarkers
for diagnosis of cancer and other disease. Cell Res. 18:997–1006.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen ZY: The expression of circulated
microRNA in ccRCC (unpublished PhD thesis). Zhongnan University;
2010
|
|
16
|
Nakada C, Matsuura K, Tsukamoto Y, et al:
Genome-wide microRNA expression profiling in renal cell carcinoma:
significant down-regulation of miR-141 and miR-200c. J Pathol.
216:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jung M, Mollenkopf HJ, Grimm C, et al:
MicroRNA profiling of clear cell renal cell cancer identifies a
robust signature to define renal malignancy. J Cell Mol Med.
13:3918–3928. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li M: MicroRNA expression profiling in
renal cell carcinoma and its potential clinical significance
(unpublished PhD thesis). Zhongshan University; 2009
|
|
19
|
Huang Y, Dai Y, Yang J, et al: Microarray
analysis of microRNA expression in renal clear cell carcinoma. Eur
J Surg Oncol. 35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Slaby O, Jancovicov J, Lakomy R, et al:
Expression of miRNA-106b in conventional renal cell carcinoma is a
potential marker for prediction of early metastasis after
nephrectomy. J Exp Clin Cancer Res. 29:902010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu H, Brannon AR, Reddy AR, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: with
application to clear cell Renal Cell Carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Juan D, Alexe G, Antes T, et al:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chow TF, Youssef YM, Lianidou E, et al:
Differential expression profiling of microRNAs and their potential
involvement in renal cell carcinoma pathogenesis. Clin Biochem.
43:150–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yi Z, Fu Y, Zhao S, Zhang X and Ma C:
Differential expression of miRNA patterns in renal cell carcinoma
and nontumorous tissues. J Cancer Res Clin Oncol. 136:855–862.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mitchell PS, Parkin RK, Kroh EM, et al:
Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei J, Gao W, Zhu CJ, et al:
Identification of plasma microRNA-21 as a biomarker for early
detection and chemosensitivity of non-small cell lung cancer. Chin
J Cancer. 30:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tomimaru Y, Equchi H, Naqano H, et al:
Circulating microRNA-21 as a novel biomarker for hepatocellular
carcinoma. J Hepatol. 56:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nam EJ, Yoon H, Kim SW, et al: MicroRNA
expression profiles in serous ovarian carcinoma. Clin Cancer Res.
14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gonzales JC, Fink LM, Goodman OB Jr,
Symanowski JT, Vogelzang NJ and Ward DC: Comparison of circulating
MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and
prostate- specific antigen for determining treatment response in
patients with metastatic prostate cancer. Clin Genitourin Cancer.
9:39–45. 2011. View Article : Google Scholar
|
|
30
|
Yaman Agaoglu F, Kovancilar M, Dizdar Y,
et al: Investigation of miR-21, miR-141, miR-221 in blood
circulation of patients with prostate cancer. Tumour Biol.
32:583–588. 2011.PubMed/NCBI
|
|
31
|
Cheng H, Zhang L, Cogdell DE, et al:
Circulating plasma MiR-141 is a novel biomarker for metastatic
colon cancer and predicts poor prognosis. PloS One. 6:e177452011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zaman MS, Shahryari V, Deng G, et al:
Up-regulation of microRNA-21 correlates with lower kidney cancer
survival. PLoS One. 7:e310602012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Boquslawska J, Wojcicka A,
Piekielko-Witkowska A, Master A and Nauman A: MiR-224 targets the
3′UTR of type 1 5′-iodothyronine deiodinase possibly contributing
to tissue hypothyroidism in renal cancer. PLoS One.
6:e245412011.
|
|
34
|
Gibbons DL, Lin W, Creighton CJ, et al:
Contextual extracellular cues promote tumor cell EMT and metastasis
by regulating miR-200 family expression. Genes Dev. 23:2140–2151.
2009. View Article : Google Scholar : PubMed/NCBI
|
